PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16495076-7	2006	SB 206553 (1 mg kg(-1) s.c.), a selective 5-HT2B/2C receptor antagonist, also inhibited the BW 723C86-mediated responses.	SB 206553	0-9	5-hydroxytryptamine receptor 2B	Rattus norvegicus	42-48
25229719-4	2015	5-HT2C receptor agonism decreases psychostimulant-mediated behaviors, and the putative 5-HT2C receptor inverse agonist, SB 206553, attenuates methamphetamine-seeking in rats.	SB 206553	120-129	5-hydroxytryptamine receptor 2C	Rattus norvegicus	87-93
25229719-7	2015	In contrast, SB 206553 and Ro 60-0175 increased evoked spiking, effects that were prevented by the 5-HT2C receptor antagonist, SB 242084.	SB 206553	13-22	5-hydroxytryptamine receptor 2C	Rattus norvegicus	99-105
24068759-5	2014	In contrast, when we applied exogenous 5-HTP (in vitro or in vivo), AADC-containing vessels and neurons synthesized 5-HT, which contributed to increased motoneuron activity and muscle spasms (long-lasting reflexes, LLRs), by acting on 5-HT2 receptors (SB206553 sensitive) located on motoneurons (TTX resistant).	SB 206553	252-260	dopa decarboxylase	Rattus norvegicus	68-72
20980537-10	2011	In contrast, inverse agonists (such as SB206553) that block constitutive activity at 5-HT(2B) or 5-HT(2C) receptors markedly reduced the LLRs, indicating the presence of constitutive activity in these receptors.	SB 206553	39-47	5-hydroxytryptamine receptor 2B	Rattus norvegicus	85-92
20165943-5	2010	Also, pretreatment with either the 5-HT(2C) receptor antagonist SB206553 or SB242084 eradicated a twofold difference in DOI-induced HTR between the standard inbred mouse strains C57BL/6J and DBA/2J, and decreased the DOI-induced HTR by at least 50% in both strains.	SB 206553	64-72	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	35-52
26244344-4	2015	In the present work, using docking and molecular dynamics methodologies, we established the most probable binding sites of SB-206553, a drug originally described as a competitive antagonist of serotonin type 2B/2C metabotropic receptors (5-HT2B/2CRs) and more recently as a positive allosteric modulator of the ionotropic alpha7 nicotinic acetylcholine receptor (nAChR).	SB 206553	123-132	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	363-368
22643326-5	2012	SB 206553 (1-10mg/kg), at 10mg/kg only, enhanced c-Fos expression in STN, striatum (except the dorsomedial part), NAcc, entopeduncular nucleus, substantia nigra pars reticulata (SNr) and compacta (SNc) and ventral tegmental area.	SB 206553	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	49-54
22697313-0	2012	SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats.	SB 206553	0-9	5-hydroxytryptamine receptor 2C	Rattus norvegicus	22-28
22697313-6	2012	To help distinguish the roles for antagonism vs. inverse agonism, here we explored the ability of a more selective 5-HT2C inverse agonist, SB 206553 to attenuate meth-seeking behavior, and compared its effects to those obtained with 5-HT2C antagonists, SDZ Ser 082 and SB 242084.	SB 206553	139-148	5-hydroxytryptamine receptor 2C	Rattus norvegicus	115-121
21223996-5	2011	5-HT2A and 5-HT2B receptor agonist-induced pMF were both blocked by selective antagonists (ketanserin and SB206553, respectively), but not by antagonists to the other receptor subtype.	SB 206553	106-114	5-hydroxytryptamine receptor 2A	Rattus norvegicus	0-6
21223996-5	2011	5-HT2A and 5-HT2B receptor agonist-induced pMF were both blocked by selective antagonists (ketanserin and SB206553, respectively), but not by antagonists to the other receptor subtype.	SB 206553	106-114	5-hydroxytryptamine receptor 2B	Rattus norvegicus	11-17
21441610-7	2011	In contrast, prolonged preexposure to the inverse agonist SB 206553 (1 muM) elevated the 5-HT-induced increase in [Ca2+]i for both isoreceptors.	SB 206553	58-67	latexin	Homo sapiens	71-74
21441610-10	2011	The different time course of SB 206553-induced resensitization of the two isoreceptors might be therapeutically relevant for drugs exhibiting inverse agonist properties at 5-HT2C receptors, such as atypical antipsychotics and certain antidepressants.	SB 206553	29-38	5-hydroxytryptamine receptor 2C	Homo sapiens	172-178
19050173-4	2009	Confirmation of the PAM activity of SB-206553 on the alpha7 nAChR was obtained in patch-clamp electrophysiological experiments in GH4C1 cells, where it failed to evoke any detectable currents when applied alone, yet dramatically potentiated the currents evoked by an EC(20) (17 microM) and EC(100) (124 microM) of acetylcholine (ACh).	SB 206553	36-45	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	60-65
18396300-7	2008	The facilitation evoked by alpha-Me-5HT was prevented by the 5HT2B/C receptor antagonist SB206553 hydrochloride (SB206553).	SB 206553	89-97	5-hydroxytryptamine receptor 2B	Homo sapiens	61-66
11166521-5	2001	The hyperactivity elicited by fluvoxamine (20 mg/kg) plus mazindol (1 mg/kg) was significantly attenuated by the 5-HT(2A) receptor antagonist M100907 (2 mg/kg) and potentiated by the 5-HT(2B/2C) receptor antagonist SB 206553 (2 mg/kg).	SB 206553	215-224	5-hydroxytryptamine receptor 2A	Rattus norvegicus	113-120
16182256-5	2006	The effect of .01 mg/kg haloperidol was potentiated by the 5-HT2C inverse agonist SB 206553 (5 mg/kg) but unaltered by the 5-HT2C antagonists SB 243213 and SB 242084 (1 mg/kg).	SB 206553	82-91	5-hydroxytryptamine receptor 2C	Rattus norvegicus	59-65
15726452-5	2005	The relaxant response to BW 723C86 was inhibited by 1 microM SB 206553 (pK(B) 6.8).	SB 206553	61-70	AKT serine/threonine kinase 1	Sus scrofa	72-76
15302781-3	2004	METHODS AND RESULTS: By mimicking sympathetic stimulation with chronic isoproterenol perfusion in vivo, we found that mice developed a cardiac hypertrophy, which was prevented by exposure to the 5-HT2B receptor antagonists SB206553 or SB215505 or in 5-HT2B receptor-knockout mice.	SB 206553	223-231	5-hydroxytryptamine (serotonin) receptor 2B	Mus musculus	195-201
15056702-5	2004	In vivo, SB 206553 (1-10 mg/kg) elicited a dose-dependent and clear-cut increase in accumbal and striatal DA release compared with SB 242084 (1-10 mg/kg), and the 5-HT2C agonist S-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine hydrochloride (Ro-60-0175) (0.3-3 mg/kg) inhibited DA release.	SB 206553	9-18	5-hydroxytryptamine receptor 2C	Rattus norvegicus	163-169
14501155-5	2003	The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect.	SB 206553	36-45	5-hydroxytryptamine (serotonin) receptor 2B	Mus musculus	4-11
8821530-17	1996	These results suggest that SB 206553 is a potent mixed 5-HT2C/5-HT2B receptor antagonist with selectivity over the 5-HT2A and all other sites studied and possesses anxiolytic-like properties.	SB 206553	27-36	5-hydroxytryptamine receptor 2A	Homo sapiens	115-121
10646521-3	2000	Basal DA efflux was enhanced (27%) by the 5-HT2A/2B/2C agonist 1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane (DOI) and reduced (-30%) by the 5-HT2B/2C antagonist SB 206553.	SB 206553	162-171	5-hydroxytryptamine receptor 2A	Rattus norvegicus	42-48
10327425-2	1999	The aim of the present study was to establish whether acute pretreatment with the selective 5-HT2C/2B antagonist SB 206553 (1, 2, and 4 mg/kg i.p.)	SB 206553	113-122	5-hydroxytryptamine receptor 2C	Homo sapiens	92-98
9225307-9	1997	These behavioural profiles suggest that blockade of the 5-HT2A receptor may not reduce anxiety and demonstrate that 5-HT2B and/or 5-HT2C receptor subtypes may be primarily involved in the anxiolytic-like effects of mianserin and SB 206553 in rats.	SB 206553	229-238	5-hydroxytryptamine receptor 2B	Rattus norvegicus	116-122
8821530-0	1996	In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.	SB 206553	32-41	5-hydroxytryptamine receptor 2B	Homo sapiens	59-74
8821530-2	1996	SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2 ,3-f]indole) displays a high affinity (pK1 7.9) for the cloned human 5-HT2C receptor expressed in HEK 293 cells and the 5-HT2B receptor (pA2 8.9) as measured in the rat stomach fundus preparation.	SB 206553	0-9	prokineticin 1	Homo sapiens	110-113
8821530-2	1996	SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2 ,3-f]indole) displays a high affinity (pK1 7.9) for the cloned human 5-HT2C receptor expressed in HEK 293 cells and the 5-HT2B receptor (pA2 8.9) as measured in the rat stomach fundus preparation.	SB 206553	0-9	5-hydroxytryptamine receptor 2B	Homo sapiens	191-206
8821530-2	1996	SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2 ,3-f]indole) displays a high affinity (pK1 7.9) for the cloned human 5-HT2C receptor expressed in HEK 293 cells and the 5-HT2B receptor (pA2 8.9) as measured in the rat stomach fundus preparation.	SB 206553	11-82	prokineticin 1	Homo sapiens	110-113
8821530-2	1996	SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2 ,3-f]indole) displays a high affinity (pK1 7.9) for the cloned human 5-HT2C receptor expressed in HEK 293 cells and the 5-HT2B receptor (pA2 8.9) as measured in the rat stomach fundus preparation.	SB 206553	11-82	5-hydroxytryptamine receptor 2B	Homo sapiens	191-206
8821530-5	1996	SB 206553 appears to be a surmountable antagonist of 5-HT-stimulated phosphoinositide hydrolysis in HEK 293 cells expressing the human 5-HT2C receptor (pKB 9.0).	SB 206553	0-9	AKT serine/threonine kinase 1	Homo sapiens	152-155
8821530-17	1996	These results suggest that SB 206553 is a potent mixed 5-HT2C/5-HT2B receptor antagonist with selectivity over the 5-HT2A and all other sites studied and possesses anxiolytic-like properties.	SB 206553	27-36	5-hydroxytryptamine receptor 2B	Homo sapiens	62-77
9582253-4	1998	In this study we have shown that intracerebral infusion of the selective 5-HT2C receptor antagonist SB 206553 (50 nmol) into the substantia nigra zona reticulata has an antiparkinsonian action in the 6-hydroxydopamine-lesioned rat model of Parkinson"s disease.	SB 206553	100-109	5-hydroxytryptamine receptor 2C	Rattus norvegicus	73-79
9582253-6	1998	Furthermore, we have demonstrated that systemic administration of selective 5-HT2C receptor antagonists SB 200646A (20 mg/kg) and SB 206553 (20 mg/kg) can potentiate the antiparkinsonian action of the dopamine D2 receptor agonist quinpirole in the 6-hydroxydopamine-lesioned rat.	SB 206553	130-139	5-hydroxytryptamine receptor 2C	Rattus norvegicus	76-82
7629791-0	1995	5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity.	SB 206553	0-70	5-hydroxytryptamine receptor 2C	Homo sapiens	80-86
7629791-0	1995	5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity.	SB 206553	0-70	5-hydroxytryptamine receptor 2B	Homo sapiens	87-93
29541541-9	2018	Additionally, treatment with the 5-HT 2C R antagonist SB243213/5-HT 2C R inverse agonist SB206553 recovered the enhanced aggressive behavior of isolated mice and returned the protein expression and immune-reactivity of ADAR1 (p110) back to the normal level.	SB 206553	89-97	adenosine deaminase, RNA-specific	Mus musculus	219-224
29541541-9	2018	Additionally, treatment with the 5-HT 2C R antagonist SB243213/5-HT 2C R inverse agonist SB206553 recovered the enhanced aggressive behavior of isolated mice and returned the protein expression and immune-reactivity of ADAR1 (p110) back to the normal level.	SB 206553	89-97	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	226-230
29541541-10	2018	Moreover, compared to the age-matched isolated mice treated with physiological saline, isolated mice treated with 5-HT 2C R inverse agonist SB206553 showed a lower percentage of Htr2c RNA editing at both A and B sites, and the same result occurred in isolated mice treated with 5-HT 2C R antagonist SB243213 at B site of Htr2c RNA editing.	SB 206553	140-148	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	178-183
29541541-10	2018	Moreover, compared to the age-matched isolated mice treated with physiological saline, isolated mice treated with 5-HT 2C R inverse agonist SB206553 showed a lower percentage of Htr2c RNA editing at both A and B sites, and the same result occurred in isolated mice treated with 5-HT 2C R antagonist SB243213 at B site of Htr2c RNA editing.	SB 206553	140-148	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	321-326
29541541-11	2018	Conclusions: The 5-HT 2C R antagonist SB243213/5-HT 2C R inverse agonist SB206553 recovered increased aggressive behavior of isolated BALB/c mice mediated by ADAR1 (p110) expression and Htr2c RNA editing.	SB 206553	73-81	adenosine deaminase, RNA-specific	Mus musculus	158-163
29541541-11	2018	Conclusions: The 5-HT 2C R antagonist SB243213/5-HT 2C R inverse agonist SB206553 recovered increased aggressive behavior of isolated BALB/c mice mediated by ADAR1 (p110) expression and Htr2c RNA editing.	SB 206553	73-81	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	165-169
29541541-11	2018	Conclusions: The 5-HT 2C R antagonist SB243213/5-HT 2C R inverse agonist SB206553 recovered increased aggressive behavior of isolated BALB/c mice mediated by ADAR1 (p110) expression and Htr2c RNA editing.	SB 206553	73-81	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	186-191